hims hers semaglutide & Introduces Access to Generic for Canadian Customers A New Era of Weight

Acknowledgements The authors thank Dr Willian Cheung, Northumbria University, for carrying out analysis of samples by LCMS

Anorectics on trial: a half century of federal regulation of prescription appetite suppressants

By the third week, 12.5% of the medication remains in your body, and the cycle continues

Your GP or provider might prescribe a 0.25-milligram dose to start

They watch the instructional video their provider sends, lay out their supplies, and take about ten minutes on that first injection

Current Research Status and Future Directions Where We Are Now (2026) Retatrutide is currently in Phase 3 clinical development under Eli Lilly's TRIUMPH program, which includes multiple trials: TRIUMPH-3 Obesity without type 2 diabetes Evaluating 12mg vs 9mg vs placebo in adults with BMI 30 or 27 with comorbidities TRIUMPH-4 Obesity with type 2 diabetes Testing efficacy and safety in patients with both conditions (preliminary: 28.7% weight loss) MASLD/NASH Trials Metabolic dysfunction-associated steatotic liver disease Leveraging glucagon's liver fat reduction effects Cardiovascular Outcomes Long-term CV safety and benefits Following precedent of STEP and SURMOUNT trials for GLP-1 drugs Timeline to FDA Approval 2023: Phase 2 results published (NEJM) 2024-2026: Phase 3 trials ongoing (TRIUMPH program) 2026-2027: Anticipated FDA submission (if trials successful) 2027-2028: Potential FDA approval and commercial launch What Researchers Are Watching The main questions Phase 3 needs to answer: Long-term efficacy: Does weight loss plateau or continue beyond 48 weeks